Overview of DESTINY-Breast06

EP: 1.Challenges in Diagnosing HER2+ Breast Cancer

EP: 2.Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

EP: 3.Preoperative Monitoring and Surgical Options for HER2+ Patients

EP: 4.Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

EP: 5.Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

EP: 6.Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

EP: 7.Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

EP: 8.Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

Now Viewing

EP: 9.Overview of DESTINY-Breast06

EP: 10.Clinical Perspectives on Managing ILD Related to T-DXd

EP: 11.Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

EP: 12.Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following questions:

• Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:
  • DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
    • Based on the above data, how might this impact practice patterns in HER2-low and HER2 ultra-low disease?
    • Would the avail of first-line T-DXd for HER2-low and HER2 ultra-low patients influence your approach in the number of regimens of endocrine therapy you recommend to patients?